The availability and prescription of a new drug for postpartum depression (PPD) will depend on how insurers cover the medication.
The expected high cost of the drug could make it inaccessible to many patients.
Providers are optimistic about the potential benefits of the drug, but still need more information regarding safety for infants and the duration of treatment effects.